Seven pre-arranged meetings and no stand: a lean first year in oncology with an estimated £300k of pipeline.
A preclinical CRO offering humanised and syngeneic mouse models and in vivo pharmacology for immuno-oncology programmes. Its buyers are discovery, pharmacology and preclinical heads at biotechs choosing models for their next IO candidates.
| Measure | Figure | Basis |
|---|---|---|
| Pre-scheduled 1:1 meetings | 7 | Included in the Exclusive 1:1 meetings package |
| Stand and session conversations | 9 | Typical range for this package |
| Total qualified conversations | 16 | Within the 15–25 meetings per sponsor at London 2026 |
| Qualified opportunities | 4 | 25% of conversations (ROI calculator default) |
| Assumed first-year deal value | £80k | Typical for this category |
| Pipeline at 90 days | about £300k | Opportunities × deal value |
| Expected wins over 6–12 months | 1 | 20% of opportunities (ROI calculator default) |
Your deal value and close rate will differ. Put your own numbers into the calculator to see the pipeline a package could create for you.
Open the ROI calculatorTell us which roles you need to meet and we will send the prospectus and current availability for San Diego, London and Boston 2027.